Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

A Hybrid AI-driven Algorithm to Uncover Potential Therapeutic Targets for COVID-19 Using Network-based Drug Repurposing

Version 1 : Received: 30 June 2022 / Approved: 1 July 2022 / Online: 1 July 2022 (05:33:16 CEST)

How to cite: Marchi, C.; Corrêa Martins Jr., D. A Hybrid AI-driven Algorithm to Uncover Potential Therapeutic Targets for COVID-19 Using Network-based Drug Repurposing. Preprints 2022, 2022070004. https://doi.org/10.20944/preprints202207.0004.v1 Marchi, C.; Corrêa Martins Jr., D. A Hybrid AI-driven Algorithm to Uncover Potential Therapeutic Targets for COVID-19 Using Network-based Drug Repurposing. Preprints 2022, 2022070004. https://doi.org/10.20944/preprints202207.0004.v1

Abstract

The COVID-19 was described as a respiratory illness, however further studies recognize it as a complex heterogeneous multisystemic disorder. Global efforts have been proposed to combat COVID-19, emerging diverse therapeutic options, in which discovering new drug therapies, development of vaccines and drug repurposing have been considered the most promising approaches to fight the virus. This study aimed to repurpose known drugs for use against the COVID-19, finding better therapeutic options. Seventeen biological databases were used in this study. The genetic algorithm (GA) was performed for a set of drug target classes and COVID-19 proteins as input, whose drug candidates are obtained according to the target similarities found in the target-target similarity predictive network, resulting in a drug-target interaction network. Thus, recommended drugs correspond to the union of the drug subsets found during each GA execution. Twenty-eight drugs were indicated to be the best therapeutic targets for the virus, in special, the Cyclosporine drug was administered as adjuvant to steroid treatment for COVID-19 patients which showed positive outcomes, reducing mortality in moderate and severe cases. The drugs found have used to treat other diseases, evidencing that the COVID-19 is a multisystemic disorder and suggests that the viruses’ mechanism of action presents some comorbidity with other human diseases. Evidence shows that the drugs found in this research might act together to fight the virus in a broader fashion, however further studies including in vitro and in vivo experiments are needed to find the best combination of these drugs.

Keywords

SARS-CoV-2; COVID-19; drug repurposing; artificial intelligence; target-target similarity network; drug-target interaction network

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.